SOURCE: Amazon Biotech, Inc

October 25, 2005 16:14 ET

Amazon Biotech Announces a New Double-blind Drug Trial Using AMZ 0026

NEW YORK, NY -- (MARKET WIRE) -- October 25, 2005 -- Amazon Biotech, Inc. (OTC BB: AMZB) today announced that it has come to an agreement with a New York City AIDS clinic to do a forty patient double-blind study using AMZ 0026 together with and in comparison with a standard cocktail currently given to patients with AIDS. Full details of the study to follow shortly.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ 0026 is the Company's first such drug, to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ 0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market. Additional information on Amazon Biotech may be found at http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor'' Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes,'' "expects,'' "anticipates,'' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information

  • CONTACT:
    LC Group
    Rick Lutz
    (404) 261-1196